Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. FDA panel backs female libido drug, with conditions

A drug to treat low female sexual desire should be approved with strict measures in place to ensure patients are fully aware of its risks, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. If approved, the drug would be the first to treat low sexual desire in women. The FDA […]

Read More »

Orexigen, Takeda file suit against Actavis to stop generic diet pill

Orexigen Therapeutics Inc and partner Takeda Pharmaceutical Co Ltd said they had filed a lawsuit against Actavis Plc to block a generic version of diet-pill Contrave. The lawsuit, filed at a Delaware district court, alleges that Actavis has infringed patents on Orexigen and Takeda’s weight-loss treatment. Contrave is one of the three weight-loss pills that […]

Read More »

2015 Annual Report: Top 100 Biotechnology Companies – The Acquisition Game

The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.

Read More »

Sales and Marketing: Facts & Figures

While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of hurdles that are impeding more rapid market uptake, according to a recently completed study by the Tufts Center for the Study of Drug Development. Fourteen years after the human genome was initially sequenced, […]

Read More »

End-of-life care

How to determine the right strategy for mature brands By Tim Arendt, Fahti Khosrow-Shahi, and Seb Morisot Tim Arendt is VP, Fahti Khosrow-Shahi is managing director, and Seb Morisot is engagement manager, Campbell Alliance. Based on current trends, soon 90 percent of products dispensed will be for a generic. As a result, companies are more […]

Read More »

Patient Communities Special Feature: Patient influence continues to rise

The growth of communities such as Inspire and PatientsLikeMe, coupled with FDA’s recent guidance on social media in pharma, point to how patients will increasingly merit pharma’s attention. When the patient community network Inspire was founded eight years ago, co-founder and CEO Brian Loew said he got a cool reception from the pharmaceutical companies he […]

Read More »

DTC Special Feature: Direct to human

The impact of Viagra’s most recent DTC campaign has brand managers talking about the “humanity” of their communications.   It is sometimes easy to forget that the audience at the other end of pharmaceutical brands’ direct to consumer communications consists of ordinary humans. For all the new technologies and channels at hand today, brand managers […]

Read More »

Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class Innovation 2015: Market Landscape to Grow in Diversity over Coming Years

DUBLIN, June 4, 2015 /PRNewswire/ — Research and Markets (http://www.researchandmarkets.com/research/tldjc5/frontier_pharma) has announced the addition of the “Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class Innovation” report to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Biologics Growing in Prominence in Asthma Treatment: While the current asthma market is almost exclusively dominated by small molecules, which account for […]

Read More »

AstraZeneca PLC’s Booming Immuno-Onco Pipeline Validates Rebuffing Pfizer

Immuno-oncology, programming or stimulating the body’s own immune system to attack cancer cells, is a technology that appears to be starting to move into the mainstream. At the American Society of Clinical Oncology (ASCO) meeting in Chicago this week, AstraZeneca PLC (AZN) and MedImmune (AZN), AstraZeneca PLC’s global biologics research and development unit, provided an […]

Read More »

Merck’s Quest To Revive The Market For Insomnia Drugs

In March, just one month after Merck introduced its new insomnia drug, Belsomra, physicians were writing 4,000 prescriptions a week for the new product—enough for CEO Kenneth Frazier to declare the launch a success during the company’s first-quarter earnings call. Excitement over the Belsomra is so high, in fact, that U.K.-based consulting firm GlobalData predicts […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom